Holen Sie sich die Stockscreener-App
29.00
4.89%
-1.49
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX) - Seeking Alpha
Can Viking Therapeutics Inc. maintain its current growth rateFed Meeting & Short-Term Swing Trade Alerts - mfd.ru
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market - Benzinga
Viking Therapeutics (VKTX) Is Up 16.0% After Fast-Tracking VK2735 Into Phase III Trials – Has The Bull Case Changed? - Yahoo Finance
Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential - Seeking Alpha
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth - 富途牛牛
Viking Therapeutics Advances VK2735 Toward Phase 3 After FDA Feedback - AD HOC NEWS
What is HC Wainwright's Forecast for VKTX Q4 Earnings? - MarketBeat
Is Viking Therapeutics (VKTX) Pricing Reflecting Recent Drug Development Progress? - simplywall.st
Viking Therapeutics' VK2735 Sees Strong Demand Amid Novo Nordisk Launch - Intellectia AI
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Pipeline Momentum Boosts Viking Therapeutics as Phase 3 Timeline Accelerates - AD HOC NEWS
Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress - Yahoo Finance
Viking Therapeutics stock rating reiterated at Buy by Laidlaw - Investing.com Nigeria
Viking Therapeutics Bets Big on Obesity Breakthroughs - TipRanks
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN
Viking Therapeutics (NASDAQ:VKTX) Shares Gap UpTime to Buy? - MarketBeat
Viking Therapeutics pushes GLP-1/GIP obesity pill to phase 3 - TechTarget
Viking to push oral GLP-1/GIP drug into phase III obesity trial - bioworld.com
Viking Therapeutics Stock Soars: What's Driving The Momentum? - Benzinga
Stock Movers: Equinix, Crocs, Viking Therapeutics - Bloomberg.com
Viking Therapeutics stock price target lowered to $118 by Raymond James By Investing.com - Investing.com Canada
Viking Therapeutics stock rating reiterated at Buy by Laidlaw By Investing.com - Investing.com South Africa
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - marketscreener.com
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $99 - 富途牛牛
Viking Therapeutics (VKTX) Shares Rise on Promising Obesity Drug Updates - GuruFocus
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Viking Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates - Yahoo Finance
Viking Therapeutics stock price target lowered to $118 by Raymond James - Investing.com
Viking Therapeutics rises after Q4 updates (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics Advances Oral Obesity Drug Toward Final Clinical Trials - AD HOC NEWS
Morgan Stanley Trims Price Target on Viking Therapeutics to $99 From $102, Keeps Overweight Rating - marketscreener.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Viking Therapeutics stock soars on plans for Phase 3 obesity drug trial - Investing.com
Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus - Bez Kabli
Viking Therapeutics, Inc. (VKTX) shares surged 11.7% in pre-market trading after the company announced plans to advance its oral obesity treatment drug to late-stage trials. - Bitget
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens - MSN
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Viking Therapeutics plans to advance oral obesity drug to late-stage testing - whbl.com
Viking Therapeutics Q4 2025 Earnings Call Highlights - Intellectia AI
Viking Therapeutics (VKTX) Advances Obesity Pipeline Amidst Fina - GuruFocus
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Inc (VKTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs - GuruFocus
Viking (VKTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Viking Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Viking Therapeutics stock climbs after Q4 report: Details - MSN
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast By Investing.com - Investing.com Nigeria
Viking Therapeutics reports Q4 EPS ($1.38), consensus (90c) - TipRanks
Viking Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast - Investing.com
How Viking’s Q4 2025 Earnings and VK2735 Weight-Loss Updates Will Impact Viking Therapeutics (VKTX) Investors - simplywall.st
Viking Therapeutics, Inc. SEC 10-K Report - TradingView
VKTX: Late-stage clinical progress and strong cash reserves position the company for future growth - TradingView
Viking Therapeutics (VKTX) Reports Q4 EPS Miss and Advances Obes - GuruFocus
Viking (VKTX) Advances Obesity Treatment with Key Developments - GuruFocus
Viking Therapeutics Q4 Loss Widens - marketscreener.com
Viking Therapeutics plans to advance oral obesity drug to late-stage trial - marketscreener.com
Earnings Flash (VKTX) Viking Therapeutics, Inc. Reports Q4 Revenue $0K - marketscreener.com
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):